Stockreport

Regeneron beats quarterly results estimates on strong Dupixent demand [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF for its ?eczema drug, Dupixent, and cancer drug, Libtayo, offsetting competitive pressures faced ?by eye drug Eylea. The company has been relying on Dupixent, which it [Read more]